Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B33cab2a60c2d70cc549e1f99da4376fe> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B33cab2a60c2d70cc549e1f99da4376fe NCIT_P378 "CDISC" @default.
- B33cab2a60c2d70cc549e1f99da4376fe type Axiom @default.
- B33cab2a60c2d70cc549e1f99da4376fe annotatedProperty NCIT_P325 @default.
- B33cab2a60c2d70cc549e1f99da4376fe annotatedSource NCIT_C49688 @default.
- B33cab2a60c2d70cc549e1f99da4376fe annotatedTarget "Later Phase 2 trials, in transition to Phase 3, where the study populations more closely reflect the population, dosage, and condition for intended use. [Clarification of FDA Guidance for industry end of Phase 2a meetings, September 2009; Discussion in Peter B. Gilbert. SOME DESIGN ISSUES IN PHASE 2B VERSUS PHASE 3 PREVENTION TRIALS FOR TESTING EFFICACY OF PRODUCTS OR CONCEPTS. Stat Med. 2010 May 10; 29(10): 1061-1071.]" @default.